CD160

CD160 antigen is a protein that in humans is encoded by the CD160 gene.[5][6][7]

CD160
Identifiers
AliasesCD160, BY55, NK1, NK28, CD160 molecule
External IDsOMIM: 604463 MGI: 1860383 HomoloGene: 5122 GeneCards: CD160
Gene location (Human)
Chr.Chromosome 1 (human)[1]
Band1q21.1Start145,719,471 bp[1]
End145,739,288 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

11126

54215

Ensembl

ENSG00000117281

ENSMUSG00000038304

UniProt

O95971

O88875

RefSeq (mRNA)

NM_007053

NM_001163496
NM_001163497
NM_018767

RefSeq (protein)

NP_008984

NP_001156968
NP_001156969
NP_061237

Location (UCSC)Chr 1: 145.72 – 145.74 MbChr 3: 96.8 – 96.83 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

CD160 is a 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules.[7]

Clinical significance

CD160 is a ligand for HVEM, and considered a proposed immune checkpoint inhibitor with anti-cancer activity along with anti- PD-1 antibodies.[8] CD160 has also been proposed as a potential new target in cases of human pathological ocular and tumor neoangiogenesis that do not respond or become resistant to existing antiangiogenic drugs.[9]

gollark: Make enemies?
gollark: Sneak it into his food?
gollark: Ultimately, it's the universe's fault.
gollark: I don't think that's a reasonable way to do rights.
gollark: However, doing fillings for free COULD cause apiocity.

See also

References

  1. GRCh38: Ensembl release 89: ENSG00000117281 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000038304 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, Patel AT, Robertson MJ, Nadler LM, Freeman GJ (Oct 1998). "Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes". J Immunol. 161 (6): 2780–90. PMID 9743336.
  6. Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, Bolton W, Ogg G, Boumsell L, Bensussan A (Apr 1999). "Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells". J Immunol. 162 (3): 1223–6. PMID 9973372.
  7. "Entrez Gene: CD160 CD160 molecule".
  8. Stecher, Carmen; Battin, Claire; Leitner, Judith; Zettl, Markus; Grabmeier-Pfistershammer, Katharina; H?ller, Christoph; Zlabinger, Gerhard J.; Steinberger, Peter (22 May 2017). "PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells". Frontiers in Immunology. 8. doi:10.3389/fimmu.2017.00572. PMC 5439058. PMID 28588576.
  9. Chabot, Sophie; Jabrane-Ferrat, Nabila; Bigot, Karine; Tabiasco, Julie; Provost, Alexandra; Golzio, Muriel; Noman, Muhammad Zaeem; Giustiniani, J?r?me; Bellard, Elisabeth; Brayer, St?phanie; Aguerre-Girr, Maryse; Meggetto, Fabienne; Giuriato, Sylvie; Malecaze, Fran?ois; Galiacy, St?phane; Ja?s, Jean-Philippe; Chose, Olivier; Kadouche, Jean; Chouaib, Salem; Teissi?, Justin; Abitbol, Marc; Bensussan, Armand; Le Bouteiller, Philippe (9 May 2011). "A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor". The Journal of Experimental Medicine. 208 (5): 973–986. doi:10.1084/jem.20100810. PMC 3092350. PMID 21482699.
  10. Klopocki E, Schulze H, Strauss G, et al. (February 2007). "Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia-absent radius syndrome". Am. J. Hum. Genet. 80 (2): 232–40. doi:10.1086/510919. PMC 1785342. PMID 17236129.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.